Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients*

Jabaudon, Matthieu; Futier, Emmanuel; Roszyk, Laurence; Chalus, Elodie; Renaud, G.; Petit, Antoine; Mrozek, Ségolène; Parratte, Sébastien; Cayot-Constantin, Sophie; Chartier, Christian; Sapin, Vincent; Bazin, Jean-Étienne; Constantin, Jean-Michel

doi:10.1097/ccm.0b013e318206b3ca

Cited by 110 publications

(114 citation statements)

References 39 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…One study has reported that sRAGE was elevated in patients with sepsis and was associated with patient outcome (23). Another study demonstrated that the sRAGE level was elevated during acute lung injury or acute respiratory distress syndrome, regardless of the presence or absence of severe sepsis (26). It has also been revealed that the level of serum sRAGE was elevated in breast cancer patients (27), and the elevated serum sRAGE levels were reported to be associated with an increased risk of cardiovascular disease in Japanese patients with type 2 diabetes (28).…”

Section: Discussionmentioning

confidence: 99%

Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer

Wang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Receptor for advanced glycation end products (RAGE) is associated with the pathogenesis of cancer progression. The pathological effects mediated through RAGE are physiologically inhibited by soluble RAGE (sRAGE). The aim of the present study was to identify the expression of the sRAGE, RAGE and RAGE ligands in serum samples and lung cancer tissue obtained from lung cancer patients. Using ELISA and immunohistochemistry, it was observed that the sRAGE levels were downregulated in the serum, the expression of RAGE was decreased in the lung cancer tissue and the RAGE ligands HMGB1 and S100 were upregulated in cancer tissue. Furthermore, the presence of several selected types of RAGE polymorphism that occur in lung cancers were measured in the tissue samples. An association between the -429T/C and 2184A/G polymorphisms of RAGE and the genesis and progression of lung cancer was identified. The comparison between various histological subtypes and stages of lung cancer was performed with the aim to clarify the biological role of the RAGE gene, and identify a biomarker to aid diagnosis and predict the prognosis for lung cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer

Wang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Later studies found an association of sRAGE with severity (29) and outcome (30) in patients with ARDS. Other investigators (31) have reported higher levels of sRAGE in ARDS patients with or without sepsis when compared to patients that only had sepsis but not ARDS. These investigators also showed a correlation of RAGE with lung injury severity, but not with outcome (31).…”

Section: Receptor For Advanced Glycation End-products (Rage)mentioning

confidence: 97%

“…Other investigators (31) have reported higher levels of sRAGE in ARDS patients with or without sepsis when compared to patients that only had sepsis but not ARDS. These investigators also showed a correlation of RAGE with lung injury severity, but not with outcome (31). A recent meta-analysis suggested sRAGE as a biomarker strongly associated with diagnosis of ARDS in a high-risk population, but not associated with mortality (16).…”

Section: Receptor For Advanced Glycation End-products (Rage)mentioning

confidence: 97%

Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise

García‐Laorden¹,

Lorente²,

Flores³

et al. 2017

Ann. Transl. Med.

102

View full text Add to dashboard Cite

Abstract:The acute respiratory distress syndrome (ARDS) is an acute inflammatory process of the lung caused by a direct or indirect insult to the alveolar-capillary membrane. Currently, ARDS is diagnosed based on a combination of clinical and physiological variables. The lack of a specific biomarker for ARDS is arguably one of the most important obstacles to progress in developing novel treatments for ARDS. In this article, we will review the current understanding of some appealing biomarkers that have been measured in human blood, bronchoalveolar lavage fluid (BALF) or exhaled gas that could be used for identifying patients with ARDS, for enrolling ARDS patients into clinical trials, or for better monitoring of patient's management. After a literature search, we identified several biomarkers that are associated with the highest sensitivity and specificity for the diagnosis or outcome prediction of ARDS: receptor for advanced glycation end-products (RAGE), angiopoietin-2 (Ang-2), surfactant protein D (SP-D), inteleukin-8, Fas and Fas ligand, procollagen peptide (PCP) I and III, octane, acetaldehyde, and 3-methylheptane. In general, these are cell-specific for epithelial or endothelial injury or involved in the inflammatory or infectious response. No biomarker or biomarkers have yet been confirmed for the diagnosis of ARDS or prediction of its prognosis.However, it is anticipated that in the near future, using biomarkers for defining ARDS, or for determining those patients who are more likely to benefit from a given therapy will have a major effect on clinical practice.

show abstract

“…Further studies suggested that the activation of RAGE plays a role in various inflammatory and infectious diseases (4)(5)(6), acute respiratory distress syndrome (ARDS), and acute lung injury (ALI) (7,8). Soluble receptor for advanced glycation end products (sRAGE) consists of the extracellular domain but lacks the trans-membrane and cytoplasmic domains of RAGE in human plasma (9). sRAGE may have an inflammatory or homeostatic role to play in lung tissue (5,10), and is studied as an effective biomarker in ARDS (8,10), ALI (8,10), lung cancer (11) and chronic obstructive pulmonary disease (12).…”

Section: Introductionmentioning

confidence: 99%

The diagnostic utility and tendency of the soluble receptor for advanced glycation end products (sRAGE) in exudative pleural effusion

2016

View full text Add to dashboard Cite

Background:The soluble receptor for advanced glycation end products (sRAGE) may have an inflammatory or homeostatic function in lung tissue. The aim of this study was to assess the usefulness of sRAGE as a diagnostic marker for exudative pleural effusions, which are common manifestations of a variety of diseases. Methods:Patients with an undiagnosed pleural effusion were prospectively enrolled between January 2013and January 2015. Samples of blood and pleural fluid were centrifuged and the supernatant stored at −70 °C.The levels of sRAGE in serum and pleural fluid were determined using a commercially available enzymelinked immunosorbent assay (ELISA) kit. Results:In total 47 patients, 21 patients were diagnosed with a tuberculous effusion, and the groups diagnosed with parapneumonic or malignant effusions comprised 13 patients each. The serum sRAGE levels for tuberculosis were significantly elevated [median, 1,291 pg/mL; interquartile range (IQR), 948-1,711 pg/mL] when compared with those for both pneumonia (median, 794 pg/mL; IQR, 700-1,255 pg/mL) and lung cancer (median, 886 pg/mL; IQR, 722-1,285 pg/mL) (P=0.029). The pleural sRAGE levels for pneumonia (median, 1,763 pg/mL; IQR, 1,262-4,431 pg/mL) were lower than those for both tuberculosis (median, 5,081 pg/mL; IQR, 3,300-6,004 pg/mL) and lung cancer (median, 4,936 pg/mL; IQR, 3,282-7,018 pg/mL) (P=0.009) The receiver operating characteristic (ROC) curve analysis selected 896 pg/mL as the best cutoff value in the sRAGE serum level for tuberculosis [sensitivity, 86%; specificity 58%; area under the curve (AUC) =0.727, P=0.008]. For the pleural effusion sRAGE level, the ROC curve analysis selected 2,231 pg/mL as the best cutoff value for pneumonia (sensitivity, 91%; specificity, 62%, AUC =0.792, P=0.002).Conclusions: Among patients with exudative effusion, pleural and serum sRAGE measurements may be useful supportive diagnostic tools in the evaluation of ambiguous pleural effusion. Furthermore, the behavior of sRAGE in the serum and pleural fluid of various pulmonary diseases suggests that sRAGE may be linked to the chronic process of lung damage and inflammation rather than acute bacterial infection.

show abstract

Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients*

Cited by 110 publications

References 39 publications

Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer

Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer

Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise

The diagnostic utility and tendency of the soluble receptor for advanced glycation end products (sRAGE) in exudative pleural effusion

Contact Info

Product

Resources

About